BioPharma Dive: The Golden Era of GLP-1 Drugs: Where We Are and What Comes Next
Optimize Your Gene Therapy Strategies With This eBook (3 Case Studies Included)
A Comprehensive Guide to Gene Therapy and Improving AAV Efficiency
Entrust your gene therapy research to an experienced CRO like Altasciences.
Our work with CRISPR gene-editing therapeutics in nonhuman primates (NHPs) encompasses a variety of administration routes, supported by our extensive bioanalytical capabilities to conduct biodistribution studies.
Find out more about:
- how to navigate the regulatory landscape;
- how to optimize the safety and efficacy of AAV-based therapies;
- Altasciences’ track record in gene therapy studies; and
- how Altasciences can support your gene therapy studies.
Three supporting case studies are included!
You may also be interested in the below:
-
The Altascientist:
- Nonclinical Studies in Cell and Gene Therapy
- Quantitative PCR (qPCR) and droplet digital (ddPCR) for Your Gene Therapy Programs
-
Webpages:
- Bioanalytical Services
- Preclinical Services
The Benefits of Liquid-Filled Capsules for Pharmaceutical Development
Are LFHCs Right for You?
The choice of dosage form for a drug product in development is critically important, as the formulation and manufacturing processes directly impact timelines. Liquid-filled, hard-shell capsules (LFHCs) offer several advantages over tablets and other solid oral dosage forms in pharmaceutical development, including ease of scalability and manufacturing, faster absorption, and higher product stability.
Opting for LFHCs could accelerate your drug development timeline.
Does your drug compound have the profile to benefit from a liquid-filled oral dosage form? Find out!
We have the expertise to quickly determine if a particular API is appropriate for an LFHC formulation. Consult with one of our experts today.
Related resources that may interest you:
- Infographic: Choosing the Optimal Dosage Form for Your Molecule
- Webpage: Altasciences’ Manufacturing and Analytical Testing Services
- eBook: Achieving Optimal Formulation for Preclinical Testing
Case Study: Innovative Nanosuspension Approach to Maximize API Potency in Preclinical Formulation Development
T-cell-dependent Antibody Responses and Immunopathology: A Comparative Study in Juvenile Cynomolgus Monkeys
Incidence of Neutralizing Adeno-Associated Viral Antibody Subtypes in Cynomolgus Monkeys of Cambodian, Mauritius, and Philippines Origins
Germline Integration Assessment in Preclinical Gene Therapy Studies
Key Considerations for Nonclinical AAV Gene Therapy Development
Achieve Faster Ophthalmic Drug Development
End-to-End Support
Altasciences has over 50 years of experience with all ophthalmic therapeutic indications. Our advanced technological platforms and comprehensive regulatory expertise support your program from lead candidate selection to market.
Our end-to-end expertise includes:
- many different types of formulations, including nanoparticles and ocular implants;
- ocular studies performed in rodent and non-rodent species;
- FIH to Phase lla focused, more than 40 ophthalmology trials completed; and
- state-of-the-art bioanalytical instrumentation and assay platforms.
Explore our full range of integrated ophthalmic drug development services and how we can accelerate your timeline by up to 40%.
Do you have an ocular drug compound in your pipeline? Speak with one of our experts and let’s get you started!
Related resources that may interest you:
- Webpage: Comprehensive Ophthalmic Drug Development Solutions
- Scientific Journal: The Complexities of Early-Phase Ophthalmic Drug Development
- Scientific Poster: Ocular Imaging and Microscopic Analysis of Focal Chorioretinal Defects in Rabbits